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Susan K. Parsons,1 Sean Phipps,2 Lillian Sung,3 K. Scott Baker,4 Michael A. Pulsipher,5
Kirsten K. Ness6The purpose of this manuscript is to summarize issues relevant to health-related quality of life (HRQL), phys-
ical function, and neurocognitive function for survivors of pediatric hematopoietic stem cell transplantation
(HCT). The physiologic and psychological demands of HCTand its sequelae have the potential to substantially
alter HRQL. When compared with research on adult HCTrecipients, research in pediatric HRQL following
HCT has lagged considerably. Initially, this lag was because of limited validated questionnaires, small numbers
of affected patients, and a general lack of salience for the topic relative to traditional endpoints, such as
transplant-related toxicity and potential mortality. The percentage of childhood HCT survivors with physical
disability ranges from 7% to 17% in studies where the outcome was based on clinician or self-report mea-
sures, to over 40% in studies where the outcome was based on a directly measured physical performance
task. Direct and comprehensive measures of physical performance may help further clarify the proportion
of individuals who have subclinical problems amenable to intervention before apparent functional loss be-
comes a problem. There is a need to include longer term survivors in such an assessment. In terms of neuro-
cognitive function, the majority of reports demonstrate relatively good function in survivors. However, it is
clear that little or no data on outcomes beyond 5 years posttransplant have been obtained, and clinicians
working with this population remain concerned regarding the cognitive functions of these survivors. Re-
search focused on these domains should attempt to better understand the prevalence of the problem using
child self-report and direct measurements of function, standardize measurement methods, and tools across
trials, obtain longer term evaluations and begin to consider interventional trials.
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Hematopoietic stem cell transplantation (HCT) is
an important therapy that has improved outcomes for
some children with cancer when prognosis is poor.
However, until recently, little attention has been paid
to the late effects of HCT. In April 2011 the National
Cancer Institute/National Heart, Lung and Blood In-
stitute, along with the Pediatric Blood and Marrow
Transplant Consortium, sponsored a consensus con-
ference of international experts in clinical and biologic
research into late effects after HCT in order to review
the state of the science of pediatric studies and identify
key areas for future research. This article represents
the fifth in a series of summary articles covering the
major topics discussed at the conference and is focused
on health-related quality of life (HRQL), functional
and neurocognitive outcomes.
Among survivors of childhood HCT, these
outcomes have several common themes. First, the
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is sparse. The existing literature is limited by the wide
variety of instruments and approaches that have been
used across trials. Second, much of the literature
includes only indirect assessments of function includ-
ing proxy reports. Third, many studies have had lim-
ited follow-up; few have described these outcomes in
very long-term survivors. Finally, concurrent medical
events that are likely to complicate these outcomes
have not been included as covariates in many of these
studies. The following sections summarize each do-
main and conclude with recommendations for future
research.
HRQL
HRQL is a multidimensional construct, grounded
in theWorld Health Organization’s 1948 definition of
health. Health is defined as not merely the absence of
disease, but rather, a state of complete physical, men-
tal, and social well-being [1]. Over time, although def-
initions of quality of life (QOL) and HRQL have
varied [2], there is general consensus about the multi-
dimensionality of the construct and its incorporation
of the subjective appraisal of one’s functioning/well-
being. In addition, the terms of QOL and HRQL
are often used interchangeably. Atlhough QOL refers
to a broader construct, including a variety of domains
within and outside of the purview of the healthcare
system, HRQL refers to the impact of the health states
on overall QOL, principally one’s own health issues
[3,4].
Multiple stakeholders can use information on
HRQL outcomes. For clinicians, it can improve our
understanding of the impact of health issues on every-
day life. It can assist in early identification of complica-
tions of treatment, serve as the basis of anticipatory
guidance, and allow for timely introduction of addi-
tional services. For researchers, HRQL can be used
to help evaluate the benefits of treatments or interven-
tions. For policy makers, HRQL can be used, particu-
larly when reported as health state preferences, in the
review of resource allocation. In the field of HCT,
HRQL studies have been largely descriptive.
Cross-sectional Studies Mark Beginning of
HRQL Investigation
Researchers first began to explore HRQL in adult
HCT survivors in the mid-1980s, producing a rich lit-
erature on the trajectories of HRQL over time, and re-
porting the factors associated with altered functioning
[5]. Research in pediatric HCT lagged behind that in
the adult population until the mid-1990s with the de-
velopment of new child self-report instruments, sev-
eral with companion parent reporting. Few of these
measures were developed solely for use in pediatric
HCT. More commonly, they were designed for usein the general pediatric population or in subpopula-
tions of children with chronic illness, and applied
successfully in populations of children with HCT. Ex-
amples are the Pediatric Quality of Life 4.0 General
Core Scales [6], the Child Health Questionnaire [7],
the Child Health Ratings Inventories-General Health
Module [8-10], and theHealth Utilities Index 2/3 [11].
Only 1 instrument was designed specifically for use
with survivors of childhood HCT, the Child Health
Ratings Inventories-HCT instrument, a 10-item
module to complement to the overall generic HRQL
instrument(s) [9,10].
Most of the early studies in children were cross-
sectional in design. Despite the variety of instruments
used in these studies, consistent results indicated that
HRQL was found to vary by time posttransplant (ear-
lier, worse), by transplant type (unrelated worse than
autologous or allogeneic related), and by presence or
absence of HCT-related sequelae (eg, worse with
chronic graft-versus-host disease [GVHD]) [9]. In
short, the early picture of children’s HRQL post-
HCT made sense and was clinically recognizable.
These early studies were important for several rea-
sons. First, despite the complexity of care and the se-
verity of the children’s state of health, researchers
were able to successfully enroll participants and effi-
ciently collect HRQL information. Second, building
on increasing interest in collecting HRQL directly
from the child rather than solely from their parent or
other proxy rater, these early studies demonstrated
that it was possible to collect valid and reliable self-
reported HRQL from the children themselves. Third,
important and not overlapping information could also
be obtained from parents whose perspective adds addi-
tional information to the overall picture of the child’s
HRQL.Longitudinal Studies Explore 12-Month HRQL
Trajectories
By the early 2000s, research in HRQL among chil-
dren with HCT shifted to longitudinal studies. The
approach to HRQL measurement in longitudinal
studies, like that in HRQL measurement in cross-
sectional studies, has not been standardized across
studies. Going forward, the field of pediatric HRQL
research may benefit from consensus about measure-
ment to allow for comparisons across studies and in
clinical trials, as reported by the National Institutes
of Health Consensus Development Project on Criteria
for Clinical Trials in Chronic Graft-versus-Host
Disease [12].
Baseline (pre-HCT) factors, such as family cohe-
sion and the child’s adaptive functioning, have been
shown to affect HRQL scores and behavioral adjust-
ment post-HCT [13]. Several groups have also identi-
fied the importance of pre-HCT parenting stress on
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16]. The trajectories of HRQL over the 12 months
following HCT, first reported in 2006 by 2 different
groups [5,17] were similar. One study by Parsons
et al. [5] demonstrated that baseline HRQL varied by
child age and program (treatment) site. The poorest
HRQL was seen at 3 months post-HCT with steady
improvement thereafter. Recipients of unrelated do-
nor transplants had the steepest declines in HRQL
from baseline to 3 months. By 12 months, HRQL
was similar across transplant types and surpassed base-
line scores. A second study by Felder-Puig et al. [17]
reported a similar HRQL trajectory. They also re-
ported that compromised emotional functioning,
high levels of worry, and reduced communication dur-
ing the acute recovery period had a negative impact on
HRQL at 1 year post-HCT. In the ‘‘Journeys to
Recovery’’ Study of 165 parent-child dyads, day 45 as-
sessments, timed to coincide with end of the initial
HCT hospitalization for the majority of recipients,
a nadir in HRQL scores was observed at day 45 for
all transplant types, although the depth of the nadir
varied by domain of HRQL [18]. This finding has
been confirmed in a subsequent sample of 200
parent-child dyads [19].
Recent longitudinal studies have identified an
association of additional baseline risk factors with
the trajectory of HRQL following HCT, including
child age (older, worse HRQL) [14,19,20], child
gender (female, worse HRQL) [20], rater (mothers re-
port lower HRQL than fathers; children report better
HRQL than parents) [18,21], concordance by primary
language or by gender of the raters (concordant pairs,
higher HRQL) [22], parental emotional distress
(greater distress, worse HRQL) [18,23], and child
race, (African American, better HRQL) [20]. Larger
studies are needed to confirm these findings in medi-
cally and demographically diverse samples. A system-
atic review of the literature, prepared by Clarke and
coworkers [24], provides an excellent summary
through 2008.Relationship between HRQL and Clinical
Factors
Few studies have documented an association be-
tween post-HCT clinical events and HRQL trajecto-
ries among pediatric survivors. This is likely to be
the result of several important factors. First, it is not
routine for researchers to collect in depth clinical out-
comes data alongside HRQL information. The pro-
cess is time consuming, requires trained study
personnel, and careful oversight to ensure complete-
ness and accuracy. Second, clinical events in pediatric
HCT, although potentially devastating, are relatively
rare, especially in contrast to their frequency in adult
recipients. Third, studies to date have not been largeenough to have sufficient power to detect meaningful
changes in HRQL because of discrete clinical events.
In earlier cross-sectional studies of a total sample
of 122 pediatric HCT recipients at a median of 1.4
years post-HCT [9,10], we demonstrated that
HRQL varied significantly by physician-rated clinical
severity (more severe, worse HRQL). Forinder et al.
[25] reported in a cross-sectional evaluation of
HRQL among 52 pediatricHCT survivors at amedian
of 8 years fromHCT [25], that children with moderate
to severe chronic GVHD reported worse HRQL. In
2006, a report on the impact of specific HCT compli-
cations on children’s HRQL indicated that HRQL
was worse among children with severe end-organ tox-
icity, systemic infection, or GVHD [5]. In subsequent
studies, we have found that the presence and severity of
clinical events explains parent-child differences in rat-
ings of the child’s HRQL at both early and later time
points in the first year post-HCT [18].
Paucity of HRQL Studies for Longer Term
Survivors
One of the striking gaps in the literature describing
HRQL among pediatric HCT recipients is the paucity
of studies beyond 12 months posttransplantation, de-
spite the fact that the majority of pediatric HCT recip-
ients are long-term survivors. Two cross-sectional
studies by Lof et al. [26] and Sanders et al. [27] report
on the HRQL among pediatric HCT survivors of 5
years or more with similar findings. In general,
HRQL is reasonably good, although psychological,
cognitive, or physical problems appear to negatively
influence HRQL. Female sex, causal diagnosis for
HCT (acute myelogenous leukemia, worse HRQL),
and intensity of pre-HCT therapy were all identified
as affecting HRQL post-HCT. Vrijmoet-Wiersma
and coworkers [16] in their 2009 cross-sectional study
of children 5 to 10 years post-HCT describe parental
concerns about the child’s vulnerability, which the au-
thors caution may induce overprotective parenting.
The 2010 review article by Baker et al. [28] provides
an excellent review of the literature on HRQL assess-
ment for pediatric HCT survivors.
Summary and Recommendations for Future
Research
We face numerous challenges going forward in the
evaluation of theHRQL for pediatric HCT recipients.
To accommodate proposed larger samples with im-
proved representativeness, we will need to enhance
the ease of data collection. Historically, we have relied
largely on in-person assessments and collected HRQL
with paper-and-pencil measures, with assessments
timed to the medical encounter. Although this ap-
proach has been successful, it is cumbersome and
resource intense. Younger children within the 5- to
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because of emerging literacy. We have explored the
use of computerized animation to facilitate data collec-
tion and minimize potential for interviewer bias
[29,30], a technique that has also been shown to be
successful in other pediatric populations. For adults
and older children, electronic data collection has
greatly facilitated the collection of HRQL. With
electronic data collection, HRQL could be collected
more frequently, such as monthly, during the periods
of most rapidly changing clinical course and then, for
studies beyond the first year, annually. If future
studies are designed to collected HRQL information
outside of the regular healthcare encounter, alter-
native access to clinical information is needed, either
through integrated medical records across sites of
care or elicitation of clinical data from parents or
older survivors.
To ensure representativeness of the sample and
generalizability of the findings, it is imperative that
we strive to collect HRQL information from families
across racial and ethnic groups, levels of formal educa-
tion and literacy, and languages. The complexity of
language and acculturation on HRQL reporting
were highlighted in the 2009 report by Feichtl and co-
workers [22], who demonstrated that parent-child
dyads speaking the same language had higher agree-
ment in HRQL than language discordant pairs. To
understand the broad picture of HCT survivorship,
we will not want to restrict our samples to the subset
of patients that might continue to receive care at the
HCT center.
Building on our 2 decades of progress in HRQL
assessment following HCT, the purpose of HRQL
measurement must be explicit. What are we trying
to understand about the complex HCT recovery pro-
cess and of that, what information can we only ob-
tain directly from our pediatric HCT recipients?
We must collectively address the issues of standard-
ization of measurement, expanded representativeness,
and rigorous approaches to analysis. We must ad-
dress the HRQL issues of longer term survivors, 1
obvious challenge of which is dealing with the tran-
sition from child-based to adult-based scales and
from proxy-rated to self-reported outcomes. Future
studies will need to address how best to capture
the full experience of HCT survivorship within the
context of ongoing clinical sequelae, as well as the
broader focus.FUNCTIONAL OUTCOMES
Chronic Disease and Physical Function
Chronic conditions that impair the structure and
or physiology of the musculoskeletal, neurological,
cardiac, pulmonary, endocrine, and integumetarysystems are prevalent in over 90% of children who
survive following HCT [31]. These impairments
have the potential to interfere with physical function
as these systems provide the foundation upon which
movement occurs. Problems with physical function
have been reported among adult survivors of child-
hood HCT; however, prevalence rates depend largely
on the measurement mechanism and on the person
who reports or documents the outcome. The litera-
ture describing observed functional loss, perceived
functional loss, and measured functional loss do not
provide consistent estimates of either the magnitude
or the severity of the problem. Clinician reports on
physical function suggest that problems are present
in less than 10% of survivors [32], and survivor self-
reports indicate only slightly higher rates of func-
tional loss (17%) [33]. However, in the few studies
where physical performance (capacity) is directly
measured, prevalence rates are markedly higher,
with estimates of the proportion of HCT survivors
who demonstrate significantly impaired physical
capacity ranging from 40% to 62% [34,35]. Studies
that rely on clinician opinion or survivor report
to estimate the degree of physical performance
limitation report mild and moderate limitations
respectively [26,36], whereas studies that measure
physical performance report more severe functional
loss [34,35,37,38].
Limitations in physical function are problematic,
not only because the ability to move is necessary for
participation in daily life, but also because poor phys-
ical health is associated with poor adherence to pre-
ventive healthcare practice. Khera et al. [39]
reported that HCT survivors with disability are
1.43 (95% confidence interval 1.11-1.85) times less
likely to adhere to preventive healthcare practices
than are those without a disability. Additionally, re-
duced performances on measures of physical capacity
are associated with increased mortality rates. Among
persons in the general population 34 to 75 years
old, all-cause mortality across a 5-year period in-
creases by 20% for every 5 kg decrease in hand grip
strength [40], and for men and women, respectively,
mortality increases by 13% and 20% for every 1 met-
abolic equivalent decrease in exercise capacity
[41,42].Clinician-Reported Physical Performance
Clinician reports of long-term disability among
childhood HCT survivors suggest that the prevalence
and severity of functional loss is low. Duell et al. [32],
using data from the European Group for Blood and
Marrow Transplantation, used the Karnofsky perfor-
mance scale to report outcomes among 647 51 year
HCT survivors. In this cohort, 40% of survivors were
younger than 18 years of age when transplanted; only
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scores\80, defined as the inability to work. Similar
low rates of clinician-graded poor functional out-
come were reported by 2 other groups [26,36].
Among 50 survivors of childhood allogeneic HCT
treated at the City of Hope National Medical
Center and Stanford University Hospital, all had
Karnofsky scores of 90 or 100 [36]. Among 73 young
adults (mean age 26 years) treated at the Karolinska
University Hospital, the median Karnofsky score 10
years post-HCT was 90 [26].Self-Reported Physical Performance
Some self-report and proxy data among survivors
of childhood HCT indicate similar low rates of func-
tional loss. Helder et al. [43] evaluated 22 survivors
of childhood allogeneic HCT (mean age at HCT 11
years, mean age at questionnaire 25 years) and re-
ported no differences between survivors’ scores and
population expected values on the physical compo-
nents of the Sickness Impact Profile, the Medical
Outcomes Survey Short Form 36 (SF-36) or the Func-
tional Assessment of Cancer Therapy—Bone Marrow
Transplant Scale. In this cohort, 3 survivors were
unemployed, but only 1 had a documented physical
disability. Michel et al. [44] compared a group of sur-
vivors transplanted for childhood leukemia (N 5 142)
to a group of childhood leukemia survivors treated
with chemotherapy alone (N 5 288). There were no
differences between the groups on the physical func-
tion and leisure scales of the Vecu et Sante Percue de
l’Adolescent et de l’enfant (8-17 year olds) or the phys-
ical function and role physical scales of the SF-36 (181
year olds).
Conversely, in the Bone Marrow Transplant Sur-
vivors Study, among 235 survivors of childhood
HCT, 17% reported long-term physical performance
limitations compared with 8.7% of a sibling compar-
ison group [33]. Additionally, Sanders et al. [27] eval-
uated physical function in 214 young adults (median
age at questionnaire 28.7 years, 118 males) who were
transplanted at a median age of 11.9 years. When
compared with age- and sex-matched controls, the
HCT survivors in this cohort scored a half a standard
deviation lower on the physical function, role physi-
cal and physical component summary subscales of
the SF-36. Lof et al. [26] also identified lower self-
reported physical health among 73 young adult (me-
dian age 26 years) HCT survivors who were a median
of 10 years from transplant. HCT survivors com-
pleted the Swedish Health-Related Quality of Life
Profile and scored significantly below population
normative values on physical functioning (90.2
HCT survivors versus 95.3 population), satisfaction
with physical health (66.0 HCT survivors versus
78.7 population) and role limitation because ofphysical health (72.7 HCT survivors versus 84.9
population).Measured Physical Performance
Objective measurements of function in the pediat-
ric HCT patient and survivor population hints that
loss of physical capacity may be amuch bigger problem
than revealed in studies that rely on either clinician or
self-report data. Most of these data are from objective
measures of cardiopulmonary fitness. Larsen et al. [35]
examined exercise capacity with cycle ergometry in
a group of 20 patients before HCT, 31 patients 1
year post-HCT, and in 70 healthy controls. Pre-
HCT patients were 6.9-25.8 years old when tested,
and post-HCT patients were 6.1-32.7 years old when
tested. Average peak oxygen consumption was 21
mL/kg/min in the pre-HCT group, 24 mL/kg/min
in the post-HCT group, and 34 mL/kg/min in the
healthy controls. Among the HCT survivors, 62% of
those with cancer diagnoses scored in the lowest
fifth percentile for peak oxygen consumption when
compared with healthy controls. Eames et al. [34] ex-
amined exercise capacity with a Bruce treadmill proto-
col in 31 survivors of pediatric HCT, a mean age of
11.7 years, and a mean time since HCT of 4.7 years.
In this cohort, 25.8% of HCT survivors had exercise
capacities in the 70% to 79% of predicted category
and 41.9% had exercise capacities in the\70% of pre-
dicted category. Hogarty et al. [37] report similar re-
sults. In their study of exercise capacity among 33
HCT survivors transplanted at a mean age of 11.3
years, they indicate that, at the 5-year post-HCT
time point, only 4 of 33 survivors scored above the
75th percentile on a serial cycle ergometry test.
Limitations on cardiopulmonary fitness testing
among survivors of pediatric HCT may be accompa-
nied by poor muscle strength and endurance. Hovi
et al. [38] examined 94 HCT survivors 1 to 2 and 6
years posttransplant and 522 age- and sex-matched
controls. Participants performed a series of strength
exercises. The number of correct repetitions on each
exercise was the outcome measure. On average,
HCT survivors scored between 1.1 and 2.0 standard
deviation scores 1 to 2 years post-HCT and between
0.6 and 1.8 SDS lower than their peers on tests of mus-
cle strength and endurance.Predictors of Poor Physical Performance
Only a few studies have evaluated the predictors of
poor physical performance. In the Bone Marrow
Transplant Survivors Study [45], associations were
found between chronic GVHD, cardiac conditions,
immune suppression, or treatment for a second malig-
nant neoplasm and poor physical performance out-
comes. In the Study done at Fred Hutchison Cancer
Figure 1. Percent of pediatric HCT survivors with poor physical func-
tion by mechanism of measurement.
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mance was associated with myeloid disease.Summary and Recommendations for Future
Research
The percentage of childhood HCT survivors with
physical disability ranges from 7% to 17% in studies
where the outcome is based on clinician or self-
report measures, to over 40% in studies where the
outcome is based on a directly measured physical per-
formance task (Figure 1). In general, scores in the few
studies where physical performance was directly mea-
sured are from 1 to 2 SD below expected in the pediat-
ric HCT survivor population. However, only 4 studies
were identified that directly measured physical perfor-
mance. Three of these studies only evaluated cardio-
pulmonary fitness. The fourth used field testing
measures to characterize fitness, rather than ‘‘gold
standard’’ or ideal direct measures of muscle strength
and cardiopulmonary fitness. Few of these studies in-
cluded survivors who had survived for 10 or more years
since transplantation. Direct and comprehensive mea-
sures of physical performance may help further clarify
the proportion of individuals who have subclinical
problems amenable to intervention before apparent
functional loss becomes a problem. There is a need
to include longer term survivors in such an assessment.
In addition, some obvious chronic problems, in-
cluding GVHD, second cancers, and heart disease,
are potentially associated with physical performance
limitations. The paucity of information that directly
identifies risk factors for poor performance outcomes
is likely because many of the study sample sizes were
very small or because pretransplant therapy for the
original cancer diagnosis was unknown. Identification
of risk factors for poor physical performance outcomes
is important so that persons at the greatest risk for loss
can be identified, and so that potential interventions
can be applied to prevent impairment before it
appears.NEUROCOGNITIVE OUTCOMES
Introduction
HCT survivors are thought to be at risk for late
neurocognitive deficits as a result of the intensity of
their treatment and exposure to a number of potentially
neurotoxic agents [46,47]. Among the agents used in
pretransplant conditioning, total-body irradiation
(TBI) has been the primary focus of those assessing
neurocognitive sequelae, but other cytotoxic condi-
tioning agents, such as busulfan and other high-dose
ablative chemotherapies are potentially neurotoxic as
well [48,49]. Central nervous system toxicities also are
associated with agents (eg, cyclosporine) commonly
used for the prophylaxis and/or treatment of GVHD
[50], although there is speculation regarding direct ef-
fects of GVHD on the central nervous system [51,52].
Study of neurocognitive and academic outcomes in
pediatric HCT has been hindered by methodologic
challenges, including the relatively small samples of
survivors at any single institution [53]. Longitudinal
studies, considered the gold standard in this setting,
have been few, and present additional challenges, in-
cluding necessary changes in test instruments as pa-
tients age. To more comprehensively address these
questions, multisite studies are in order, but to date,
none has been reported. A small literature on neuro-
cognitive outcomes in HCT has developed, but most
studies remain limited by small sample sizes, retro-
spective designs, or other methodologic difficulties.
The findings reported thus far have been contradic-
tory, but a consensus is beginning to emerge (still chal-
lenged by some) that points to a relatively benign
outcome [53].Current State of Knowledge
The currently available studies on neurocognitive
outcome are not sufficient to allow for meta-analysis,
but a review suggests a smaller number of studies
that report declines in cognitive function following
HCT [54-59]. Those studies reporting declines tend
to include samples with a high percentage of very
young children. However, the preponderance of
studies report normal neurodevelopment, with no
evidence of decline [60-68]. Kramer and colleagues
[56] reported a significant decline in IQ in their cohort
at 1 year post-HCT, and these deficits were main-
tained at 3 years post-HCT [55]. Theirs was a very
young sample, with the majority of patients under 5
years of age at the time of transplant. Similarly, studies
from Sweden have reported deficits in visual-spatial
domains and executive functioning in very young chil-
dren who were transplanted with TBI [58,59].
In contrast, Phipps et al. [64-66] have reported on
the largest longitudinal cohort to date, with follow-up
through 5 years posttransplant, describing remarkable
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achievement over that time frame. Phipps et al. [64-
66] reported poorer outcome in patients undergoing
unrelated donor transplant, in those who received
TBI, and in those who experience GVHD, but these
effects were small, compared with the much larger
effects seen based on differences in socioeconomic
status [66]. The majority of studies report similar out-
comes. Simms et al. [68] reported normal cognitive
function and academic achievement in a cohort of 47
patients followed prospectively through 2 years post-
HCT. Likewise, Kupst et al. [62] noted stable
cognitive function in a large cohort followed from pre-
transplant to 2 years post-HCT. In smaller studies,
Arvidson et al. [60] and Llach et al. [63] have reported
similar normal functioning and absence of declines
over time in HCT survivors. Barrera and colleagues
[61] reported that HCT survivors did not differ from
their siblings in cognitive and academic function,
with the exception that survivors performed better
than siblings on measures of perceptual organization.
Based in these findings, we have concluded that
HCT poses low to minimal risk for late cognitive
and academic deficits in survivors.Gaps in Current Knowledge
Although the above conclusion is reasonably sup-
ported by currently available data, it must be consid-
ered tentative with several caveats. We would
highlight 3 areas that clearly call for additional re-
search. First, the literature to date has been focused
on global cognitive outcomes such as IQ and aca-
demic achievement, and there has been minimal at-
tention to specific neuropsychological functions,
such as attention, processing speed, or working mem-
ory. Current research examining cognitive outcomes
in children treated for acute lymphoblastic leukemia
and brain tumors has highlighted the need to move
from global to specific functions, which is important
in understanding mechanisms which might point to
targets for intervention [69,70]. It will be important
to examine specific neuropsychologic functions
in HCT survivors, focusing on the most likely
candidate domains (executive functions, processing
speed) to ensure that more subtle difficulties are not
being missed. The second gap involves identifying
the most important subgroups at potential risk. The
subgroup continues to pose the greatest potential
risk are the youngest children who receive TBI.
This group poses a challenge because some
executive functions are more difficult to assess in
very young children, or are assessed differently over
time as children age. Development of an accepted
standard approach to assessment of the youngest
children in this setting is needed. Subsequently, it
will be necessary to accrue much larger numbers ofpatients in this age range, requiring multisite
studies. Finally, and we believe, most importantly,
data are needed from patients as they move beyond
5 years posttransplantation. Little or nothing is
known regarding cognitive functions in such long-
term survivors. We cannot assume that the relative
stability observed through 5 years will be maintained
indefinitely. Evidence is accumulating that brain tu-
mor survivors continue to show declines many years
following completion of therapy [69], and thus it is
possible that the relatively benign outcomes observed
to date in HCT survivors may be followed by declines
much later in the survival trajectory.
Emerging New Data
Given the remaining questions, it is concerning
that there has been no new data reported in recent
years. Several reports were published in early 2008
[57,59,61,66], but to our knowledge, not a single
empiric paper examining neurocognitive outcomes in
HCT has been reported in the 3 years since then.
Recent research with acute lymphoblastic leukemia
and brain tumor populations has been focusing on
the development of interventions to prevent or
remediate cognitive late effects, and could be applied
to HCT survivors as well. These interventions
comprise 3 different approaches: (1) traditional
cognitive remediation approaches including massed
practice [71], (2) pharmacologic interventions with
medications such as stimulants [72], and (3) computer-
ized interventions targeting working memory [73].
There are pros and cons to each of these approaches,
but at present, the computerized interventions appear
to hold the most promise and are the most widely
studied, with several new clinical trials just getting
underway [69,70,73].
Screening and Management
The available data suggest that comprehensive
neuropsychologic assessments obtained intermit-
tently are no longer necessary as a standard of care.
An interview assessment of the child’s school perfor-
mance, supplemented by parental questionnaire data
should be sufficient in most cases. Well-validated
survey instruments such as the Behavioral Assessment
Scale of Children [74] or the Behavioral Rating In-
ventory Executive Function [75] provide much rele-
vant information for the clinician. Exceptions to
this approach might be made for children who were
younger than 5 years at the time of transplant, partic-
ularly if they received TBI, and those for whom cog-
nitive problems have already been identified. For
those children, and those for whom problems are
identified via interview or questionnaire, referral for
more comprehensive psychologic assessment would
be indicated.
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FUTURE RESEARCH
The absence of research reports in this area over
the past 3 years suggests some investigators may feel
the major questions have been answered. However, it
is clear that little or no data on outcomes beyond 5
years posttransplantation have been obtained, and cli-
nicians working with this population remain con-
cerned regarding the cognitive functions of these
survivors. Thus we suggest the area of highest re-
search priority at this time is a focus on very long-
term HCT survivors. Such a study should include
both performance-based measures and survey ap-
proaches, and include assessment of specific neuro-
psychologic functions as well as global outcomes.
This would be best approached in a multisite study
to generate a sufficient sample within a reasonable
time frame.CONCLUSIONS
These 3 areas—HRQL, functional outcomes and
neurocognitive outcomes—are important issues for
pediatric HCT survivors, and future research in these
domains should be a priority. We need to conduct
large multicenter studies which follow children post-
HCT longitudinally and obtain direct measures of
function. Very long-term follow-up is an important is-
sue. We need to start to consider the issue of concur-
rent medical events to better understand who is at
greatest risk for poor outcomes. Finally, we need to be-
gin to plan and develop interventional trials for those
at the highest risk of poor outcomes.ACKNOWLEDGMENTS
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